Sanders Corazon (Corsee) D. 4

What Happened
Corsee D. Sanders, a director of Ultragenyx Pharmaceutical Inc. (RARE), sold 2,000 shares of common stock in an open-market transaction on June 15, 2026. The shares were disposed at $25.05 per share for a total value of $50,100. This was a sale (not a purchase or option exercise); insider sales can be routine and the filing does not state a specific reason for the transaction.

Key Details

• Transaction date and price: 2026-06-15 — sale of 2,000 shares at $25.05 each.
• Total proceeds: $50,100.
• Shares owned after transaction: not disclosed in the Form 4 provided.
• Footnote: F1 notes that reported holdings include previously reported shares underlying RSUs that remain subject to certain vesting conditions.
• Filing timeliness: transaction and report date are both 2026-06-15; no late filing is indicated in the record.
• Transaction type: Open-market sale (SEC transaction code S); no exercise, gift, or 10b5-1 plan is disclosed.

Context
This was a straight sale by a company director — not an options exercise or a gift. The filing gives no additional explanation for the sale (e.g., 10b5-1 plan or tax-related withholding). Retail investors should view single insider sales as informational but not definitive proof of company direction; consider this alongside other insider activity and company fundamentals.